A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease

Completed · Phase 3

Conditions studied: Parkinson's Disease

In brief

The objective of this trial was to assess subject preference for PARCOPA, carbidopa/levodopa Orally Disintegrating Tablets (ODT), compared with conventional carbidopa/levodopa tablets, in subjects with stable Parkinson's disease.

Key facts

Study ID

NCT00139867

Run by

UCB Pharma

Starts

2004-01-01

Expected to finish

2004-05-01

Last updated by the study team

2014-10-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Stable Parkinson's Disease

You may not qualify if…

• Not using carbidopa/levodopa tablets

Where it is running

• Schwarz — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.